Systematic Pan-Cancer Analysis Identifies PHF6 as an Immunological and Prognostic Biomarker
Diagnostics · 29.12.2025 · 16 (1) · 110
DOI: 10.3390/diagnostics16010110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 29.12.2025. Verfasst von Yi Tao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Key Research and Development Program of China, Ministry of Science and Technology of the People’s Republic of China under the National Key Research and Development Program of China.
Abstract (Originalsprache)
Background/Objectives: PHF6 is a chromatin-binding protein located in the nucleus, and it is involved in transcriptional regulation. However, limited research exists on the specific roles and mechanisms of PHF6 across various tumors.
Methods
Based on The Cancer Genome Atlas (TCGA) database, we analyzed PHF6 expression in pan-cancer. We first evaluated the relevance between PHF6 and prognosis; then, the relevance between PHF6 and immune cell infiltration in pan-cancer were analyzed. Subsequently, we explored the correlation between PHF6 and cancer heterogeneity, such as tumor mutation burden (TMB) and microsatellite instability (MSI), as well as cancer stemness. Finally, the role of PHF6 was validated in liver cancer and pancreatic cancer cell lines by cell proliferation assays.
Results
PHF6 expression was higher in the vast majority of cancers than their normal counterparts. PHF6 was substantially correlated with prognosis and immune cell infiltration in various cancers. Moreover, PHF6 expression showed a strong correlation with cancer heterogeneity and stemness in certain cancer types. Additionally, the depletion of PHF6 inhibited cell proliferation in both liver and pancreatic cancer cells.
Conclusions
PHF6 expression was closely associated with the occurrence and development of many types of cancer, and it might promote cancer progression by inhibiting the function of the immune microenvironment, while knockout of PHF6 significantly inhibited the tumor cells proliferation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Zixin Guo
Förderung
- The National Key Research and Development Program of China
- Ministry of Science and Technology of the People’s Republic of China under the National Key Research and Development Program of China
Zitieren
APA
Tao, Y., Hu, M., Guo, Z., Xu, Q., Niu, L., Mao, Y., & Yuan, G. (2025). Systematic Pan-Cancer Analysis Identifies PHF6 as an Immunological and Prognostic Biomarker. Diagnostics, 16(1), 110. https://doi.org/10.3390/diagnostics16010110
Vancouver
Tao Y, Hu M, Guo Z, Xu Q, Niu L, Mao Y, et al. Systematic Pan-Cancer Analysis Identifies PHF6 as an Immunological and Prognostic Biomarker. Diagnostics. 2025;16(1):110. doi:10.3390/diagnostics16010110
BibTeX
@article{Tao2025,
author = {Tao, Yi and Hu, Mingming and Guo, Zixin and Xu, Qian and Niu, Lu and Mao, Yonghong and Yuan, Gang},
title = {Systematic Pan-Cancer Analysis Identifies PHF6 as an Immunological and Prognostic Biomarker},
journal = {Diagnostics},
year = {2025},
volume = {16},
number = {1},
pages = {110},
doi = {10.3390/diagnostics16010110}
}
EUVIMED